Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study )

NANot yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions

Coronary Heart Disease

Interventions

DEVICE

drug coated balloon

Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds.

DEVICE

drug eluted stent

with regular techniques

Trial Locations (1)

Nanjing First Hospital, Nanjing

All Listed Sponsors

lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT04119986 - Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study ) | Biotech Hunter | Biotech Hunter